• slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • 20
    10/17
    NEWS
    Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics...
    Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A...
  • PRESS RELEASE
    TRIBUTE study shows superiority of Chiesi’s Trimbow® (Beclometasone...
    Chiesi completed a long-term clinical study with its extrafine fixed-dose triple combination inhaler (Trimbow®) in a single...